Publication:
Cerebrospinal Fluid Total Tau Protein Levels in Patients With Multiple Sclerosis

dc.authorscopusid23062131200
dc.authorscopusid6701577980
dc.authorscopusid13610901400
dc.authorscopusid6603649059
dc.contributor.authorTerzi, M.
dc.contributor.authorBirinci, A.
dc.contributor.authorÇetinkaya, E.
dc.contributor.authorOnar, M.
dc.date.accessioned2020-06-21T15:20:22Z
dc.date.available2020-06-21T15:20:22Z
dc.date.issued2007
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Terzi] Murat, Department of Neurology, Ondokuz Mayis Üniversitesi, Samsun, Turkey, Department of Neurology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Birinci] Asuman, Department of Microbiology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Çetinkaya] Ebru, Department of Microbiology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Onar] Musa Kazım, Department of Neurology, Ondokuz Mayis Üniversitesi, Samsun, Turkeyen_US
dc.description.abstractBackground - Tau protein is present in the microtubules of axons. Markers of various types have been used to demonstrate multiple sclerosis (MS) activity and axonal damage. This study aimed to demonstrate the association between cerebrospinal fluid (CSF) tau protein concentrations and clinical prognosis in MS patients. Methods - We included 45 patients that were diagnosed according to the McDonald's criteria. The control group was made up of 38 patients that had no signs or symptoms related to the primary central nervous system lesion correlated with the patient group. CSF total tau protein was measured using the ELISA method based on the sandwich method with Innogenetics Innotest hTau antigen kit in pg/ml type. Results - In the patient group, the mean CSF total tau protein level was 238.66 ± 237.44, whereas it was 93.65 ± 82.14 in the control group. The mean total tau protein was higher in the three clinical forms when compared with the control group and it was statistically significant (P < 0.05). Conclusions - High tau protein level may be an early marker of axonal damage and this marker may be used for monitoring axon preventing therapies in the follow-up. © 2007 The Authors.en_US
dc.identifier.doi10.1111/j.1600-0404.2007.00782.x
dc.identifier.endpage330en_US
dc.identifier.issn0001-6314
dc.identifier.issn1600-0404
dc.identifier.issue5en_US
dc.identifier.pmid17489943
dc.identifier.scopus2-s2.0-34247855864
dc.identifier.scopusqualityQ1
dc.identifier.startpage325en_US
dc.identifier.urihttps://doi.org/10.1111/j.1600-0404.2007.00782.x
dc.identifier.volume115en_US
dc.identifier.wosWOS:000246198900006
dc.identifier.wosqualityQ2
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofActa Neurologica Scandinavicaen_US
dc.relation.journalActa Neurologica Scandinavicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAxonal Damageen_US
dc.subjectMultiple Sclerosisen_US
dc.subjectTauen_US
dc.titleCerebrospinal Fluid Total Tau Protein Levels in Patients With Multiple Sclerosisen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files